rethinkTHC Search
Menu
Study breakdown

Phase 1 trial maps CBD drug interactions with three common epilepsy medications

Randomized Controlled TrialStrong evidence
The takeaway

CBD had little effect on clobazam itself but tripled its active metabolite levels, slightly increased stiripentol exposure, and had no clinically relevant effect on valproate.

Epileptologists, clinical pharmacologists, and patients on CBD plus AEDs.

3.4-fold clobazam metabolite increase

What the researchers found

CBD increased N-desmethylclobazam (active clobazam metabolite) 3.4-fold for both Cmax and AUC. Stiripentol exposure increased modestly (Cmax 1.3-fold, AUC 1.6-fold). No clinically relevant effect on valproate. Clobazam increased 7-OH-CBD levels 1.5-1.7-fold. Stiripentol slightly decreased CBD metabolite levels. CBD was moderately well tolerated with all three AEDs.

Why it matters

These three AEDs are among the most commonly co-prescribed with CBD for Lennox-Gastaut and Dravet syndromes. Knowing that CBD triples the active clobazam metabolite is clinically actionable: clobazam doses may need reduction when adding CBD.

The numbers in context

N-desmethylclobazam: Cmax and AUC 3.4-fold increase. Clobazam: 1.2-fold increase. Stiripentol: Cmax 1.3-fold, AUC 1.6-fold. Valproate: no relevant change. 7-OH-CBD with clobazam: Cmax 1.7-fold, AUC 1.5-fold.

How the study worked

Phase 1, open-label, fixed-sequence drug-drug interaction study in healthy volunteers, examining bidirectional pharmacokinetic interactions between pharmaceutical CBD (Epidiolex) and clobazam, stiripentol, and valproate at steady state.

What this study cannot tell us

Healthy volunteers, not epilepsy patients. Single-dose escalation design. Cannot assess whether interactions change with chronic dosing or in patients with hepatic impairment.

How to read the evidence

Strong: well-designed Phase 1 PK study from the Epidiolex manufacturer with bidirectional interaction data.

When this study was published

Published in 2019.

The bigger picture

The somnolence commonly attributed to CBD in epilepsy may partly be caused by the 3.4-fold increase in the active clobazam metabolite. Understanding these interactions allows dose adjustments that could improve tolerability.

Questions still open

  • Should clobazam doses be routinely reduced when CBD is added? Do these pharmacokinetic interactions translate to meaningful clinical differences in seizure control?

Common questions

Does CBD interact with clobazam?
Yes, CBD tripled blood levels of clobazam's active metabolite (N-desmethylclobazam), which may increase side effects like sedation. Clobazam dose reduction may be needed when adding CBD.
Is it safe to take CBD with valproate?
This study found no clinically relevant pharmacokinetic interaction between CBD and valproate, suggesting the combination is likely safe from an interaction standpoint.

Read the original research

A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects.

Clinical pharmacology in drug development, 8(8), 1009-1031

Citation

Morrison, Gilmour; Crockett, Julie; Blakey, Graham; Sommerville, Kenneth. (2019). A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects.. Clinical pharmacology in drug development, 8(8), 1009-1031. https://doi.org/10.1002/cpdd.665

Explore the wider topic